We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » BMS Gets FDA Breakthrough Designation for Investigational HIV Blocker
BMS Gets FDA Breakthrough Designation for Investigational HIV Blocker
Bristol-Myers Squibb has received breakthrough therapy designation from the FDA for its first-in-class investigational BMS-663068 compound for use in preventing HIV infection.